<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>TABLE 1</label>
 <caption>
  <p>Compounds with antiviral activity against human and animal coronaviruses.</p>
 </caption>
 <table frame="hsides" rules="groups" cellspacing="5" cellpadding="5">
  <thead>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Compound</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibition step</td>
    <td valign="top" align="center" rowspan="1" colspan="1">EC50 or inhibition (%)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">CoVs</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Advantges and/or limitations</td>
    <td valign="top" align="left" rowspan="1" colspan="1">References</td>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">NAAE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.5 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, evaluated 
     <italic>in silico</italic>, easily produced but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B99" ref-type="bibr">Huentelman et al., 2004b</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Glycyrrhizin</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">300 mg L
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Natural molecule, highly tolerated but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B46" ref-type="bibr">Cinatl et al., 2003</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">2-acetamido-α-
     <sc>D</sc>-Glucopyranosylamine derivative
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">40 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Semi-synthetic molecule, highly tolerated, and more potent inhibitor but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B92" ref-type="bibr">Hoever et al., 2005</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Tetrahydroquinoline oxocarbazate (CID 23631927)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry (Cathepsin L)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">273 nM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B194" ref-type="bibr">Shah et al., 2010</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">SSAA09E1</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">6.7 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">SSAA09E2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">3.1 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">SSAA09E3</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">9.7 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Emodin</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry and Post-Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">50 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Natural molecule, highly tolerated but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B91" ref-type="bibr">Ho et al., 2007</xref>; 
     <xref rid="B193" ref-type="bibr">Schwarz et al., 2011</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Griffithsin (GRFT)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.16 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCoV-OC43</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Natural molecule, highly tolerated, with a broad-spectrum effect (human and animal CoVs); protected against infection and improved survival in animal assay (Balb/c)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B158" ref-type="bibr">O’Keefe et al., 2010</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.18 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCoV-229E</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.61 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.032 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.057 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">BCoV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.23 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">MHV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Eremomycin derivate 27</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">5.4 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">FIPV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">The precursor molecule (Eremomycin) is used to treat bacterial infections; may facilitate clinical assays, but knowledge of the mechanism of action is lacking</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B15" ref-type="bibr">Balzarini et al., 2006</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">14 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Eremomycin derivate 39</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">12 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">FIPV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">22 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Mucroporin-M1</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">14.46 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, moderately tolerated, easily produced but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B131" ref-type="bibr">Li et al., 2011</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Tyr-Lys-Tyr-Arg-Tyr-Leu</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">14 mM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule specifically designed to bind S protein of SARS-CoV; highly tolerated, does not impair ACE2 activity but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B208" ref-type="bibr">Struck et al., 2012</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">14 mM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">TAPI-2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">65%</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Good effects in vitro assays but had no effect on 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B84" ref-type="bibr">Haga et al., 2010</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Monoclonal antibody 47D11</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Entry</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.57 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Human antibody, specifically to SARS-CoV-2, highly tolerated and easily applicable</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B231" ref-type="bibr">Wang et al., 2020a</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">AVLQSGFR</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">2.7 × 10
     <sup>–2</sup> mg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B69" ref-type="bibr">Gan et al., 2006</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Phe-Phe dipeptide inhibitor C (JMF1521)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.18 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B202" ref-type="bibr">Shie et al., 2005</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Dipeptidyl EP128533</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">3.6 μM or 1.4 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but has contrasting effects in the literature and did not inhibit the virus in 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B256" ref-type="bibr">Zhang et al., 2006</xref>; 
     <xref rid="B55" ref-type="bibr">Day et al., 2009</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">GC373</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.2 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCoV-229E</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, seems to interact with SARS-CoV 3CLpro, but there are no 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B115" ref-type="bibr">Kim et al., 2012</xref>, 
     <xref rid="B116" ref-type="bibr">2013</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">0.3 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">FIPV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">2 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">MHV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">0.3 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">TGEV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">0.7 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">BCV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">0.15 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">FCoV-WSU</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">GC376</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.15 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCoV-229E</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, seems to interact with SARS-CoV 3CLpro, but there are no 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B115" ref-type="bibr">Kim et al., 2012</xref>, 
     <xref rid="B116" ref-type="bibr">2013</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">0.2 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">FIPV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">1.1 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">MHV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">0.15 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">TGEV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">0.6 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">BCV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">0.40 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">FCoV-WSU</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">6-azauridine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">32 nM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, but there are no 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B174" ref-type="bibr">Pyrc et al., 2006</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">2-(benzylthio)-6-oxo-4-phenyl-1,6-dihydropyrimidine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">NE</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, but there are no in vivo assays</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B176" ref-type="bibr">Ramajayam et al., 2010</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">β-
     <sc>D</sc>-N
     <sup>4</sup>-hydroxycytidine
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">10 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, and improved pulmonary function and decreased viral load in lung of infected mice</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B17" ref-type="bibr">Barnard et al., 2004</xref>; 
     <xref rid="B199" ref-type="bibr">Sheahan et al., 2020b</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">400 nM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.08–0.3 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.024 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Ribavirin</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">20 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, good results in MERS-CoV. However, meta-analyses indicate limited efficacy.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B187" ref-type="bibr">Saijo et al., 2005</xref>; 
     <xref rid="B16" ref-type="bibr">Barnard et al., 2006</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Acyclic sugar scaffold of acyclovir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">23 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, but there are no 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B163" ref-type="bibr">Peters et al., 2015</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1">8.8 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, derivate from Acyclovir, easily produced, but there are no in vivo assays</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Niclosamide</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.1 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Drug already in use to treat helminthic infections; good inhibition 
     <italic>in vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B245" ref-type="bibr">Wu et al., 2004</xref>; 
     <xref rid="B238" ref-type="bibr">Wen et al., 2007</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Mycophenolic acid (MPA)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">2.87 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Good effects 
     <italic>in vitro</italic> with MERS-CoV but did not inhibit SARS-CoV in 
     <italic>in vitro</italic> and 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B46" ref-type="bibr">Cinatl et al., 2003</xref>; 
     <xref rid="B16" ref-type="bibr">Barnard et al., 2006</xref>; 
     <xref rid="B87" ref-type="bibr">Hart et al., 2014</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">TP29 peptide</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">60 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">MHV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibited two species of CoV in mice; also improved survival and induced INF-I. Inhibited CoV in cell lines. Synthetic compound designed for nonstructural proteins.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B235" ref-type="bibr">Wang et al., 2015</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">200 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Bananins</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Replication</td>
    <td valign="top" align="center" rowspan="1" colspan="1">&lt;10 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, but there are no 
     <italic>in vivo</italic> assays
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B214" ref-type="bibr">Tanner et al., 2005</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Nitazoxanide</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Host Enzymes</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.92 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Drug already in use to treat viral infections; good inhibition 
     <italic>in vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B185" ref-type="bibr">Rossignol, 2016</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Tizoxanide</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Host Enzymes</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.83 μg mL
     <sup>–1</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Drug derived from Nitazoxanide; good inhibition 
     <italic>in vitro</italic>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B185" ref-type="bibr">Rossignol, 2016</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Saracatinib</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Tyrosine Kinases</td>
    <td valign="top" align="center" rowspan="1" colspan="1">2.9 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, used to treat Alzheimer’s disease and easily produced but there are no in vivo assays</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B203" ref-type="bibr">Shin et al., 2018</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Cyclosporin A (CsA)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Hosts Cyclophilin Family Enzymes</td>
    <td valign="top" align="center" rowspan="1" colspan="1">9–32 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV, MERS-CoV and MHV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Drug already used to treat several chronic and infectious diseases with broad-spectrum activity among CoVs</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B59" ref-type="bibr">de Wilde et al., 2011</xref>, 
     <xref rid="B58" ref-type="bibr">2013</xref>; 
     <xref rid="B165" ref-type="bibr">Pfefferle et al., 2011</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Alisporivir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Hosts Cyclophilin Family Enzymes</td>
    <td valign="top" align="center" rowspan="1" colspan="1">8.3 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Analog of CsA and has a strong inhibition 
     <italic>in vitro</italic> against SARS-CoV and other CoVs
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B56" ref-type="bibr">de Wilde et al., 2017</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Interference RNA (iRNAs)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Viral Proteins Translation</td>
    <td valign="top" align="center" rowspan="1" colspan="1">70%</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Different approach, specific targeting of viral proteins; can block replication steps and has no cytotoxicity</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B6" ref-type="bibr">Åkerström et al., 2007</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="justify" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Viral Proteins Translation</td>
    <td valign="top" align="center" rowspan="1" colspan="1">99%</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SECoV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Different approach, specific targeting of viral proteins; can block replication steps and has no cytotoxicity</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B130" ref-type="bibr">Li et al., 2019</xref>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <attrib>
   <italic>EC50: effective concentration of 50%; NE: not evaluated.</italic>
  </attrib>
 </table-wrap-foot>
</table-wrap>
